Analysts’ Viewpoint
The global penicillin G acylase market is experiencing robust growth due to increase in demand for semisynthetic penicillin, such as ampicillin and amoxicillin, which have greater efficacy and reduced toxicity compared to natural penicillin. Increase in demand for antibiotics due to rise in prevalence of infectious diseases, surge in healthcare expenditure, and increase in research & development activities to improve effectiveness of penicillin G acylase are propelling market development.
Increase in demand for semi-synthetic penicillin and rise in demand for enzyme-based manufacturing processes are likely to provide lucrative opportunities for market players in the next few years. Companies are focusing on sustainable manufacturing processes for the development of cost-effective and environmentally friendly enzymes. However, availability of alternative antibiotics and high cost of enzyme production process are likely to restrain penicillin G acylase market demand.
Penicillin G acylase (PGA) is an enzyme utilized in the manufacture of semisynthetic antibiotics such as amoxicillin, ampicillin, and cephalosporins. Demand for PGA is driven by rise in need for antibiotics and advancements in the production processes that incorporate PGA.
Beta-lactams represent the most important group of antibiotics, and account for 65% of the global antibiotic market. There has been high and sustained interest in penicillin G acylase in the last few decades. Rise in demand for P-lactam antibiotics is fueling market expansion. Increasing demand for penicillin G acylase in the global antibiotics market is ascribed to its ability to catalytically hydrolyze penicillin G into phenylacetic acid and 6-amino penicillanic acid, as well as synthesize semi-synthetic antibiotics. Furthermore, penicillin G acylase enzyme is capable of hydrolyzing cephalosporin G to produce 7-Amino-3-methyl-3-cephem-4-carboxylic acid (7- ADCA). These two key intermediates—6-aminopenicillanic acid and 7-Amino-3-methyl-3-cephem-4-carboxylic acid—are essential components in the production of semi-synthetic beta lactam antibiotics.
The latest trends in the penicillin G acylase market include development of new and improved PGA-based production processes, such as immobilized PGA and use of recombinant DNA technology, to improve efficiency and reduce costs. There is also a growing interest in the usage of PGA in other applications, such as synthesis of chiral compounds for the pharmaceutical industry.
Rise in prevalence of infectious diseases is bolstering the global penicillin G acylase industry growth. Penicillin G acylase plays a significant role in the manufacture of semisynthetic penicillin, which is a commonly used class of antibiotics. Penicillin G acylase is an enzyme that speeds up the process of breaking down penicillin G into 6-aminopenicillanic acid (6-APA), a crucial intermediate in the synthesis of semisynthetic penicillin.
The global burden of infectious diseases has increased in the past few years due to various factors such as globalization, climate change, and antimicrobial resistance. Leading causes of morbidity and mortality globally, such as tuberculosis, malaria, and HIV/AIDS, are still prevalent, according to the World Health Organization (WHO). The need for effective treatment options has become more urgent, particularly with the emergence and spread of new infectious diseases such as COVID-19.
Semisynthetic penicillin is a vital tool in treating bacterial infections, as it offers better effectiveness and broader spectrum of activity than natural penicillin, making it suitable for treating a range of bacterial infections. Therefore, demand for semisynthetic penicillin is increasing, which in turn is driving the need for penicillin G acylase as a key enzyme in its production.
Increase in demand for semisynthetic penicillin is driving the global penicillin G acylase market. Semisynthetic penicillin is able to penetrate the bacterial cell wall more efficiently than natural penicillin due to the addition of chemical groups that enhance its ability to cross biological membranes. This enables it to achieve higher concentrations within bacterial cells, leading to better bacterial killing. Furthermore, the chemical modifications made in semisynthetic penicillin make it more resistant to degradation by bacterial enzymes, ensuring its activity for longer periods.
Semisynthetic penicillin also has a better safety profile compared to natural penicillin. It is less likely to cause allergic reactions and has lower nephrotoxicity and neurotoxicity, and is thus the preferred choice for treating bacterial infections in patients who are allergic or intolerant to natural penicillin.
In terms of source, the E. coli segment dominated the global market in 2022. Microbial synthesis of PGA, either in its natural strain or in recombinant hosts, has received much attention, particularly for PGA from E. coli. Hence, extensive research & development activities to enhance the recovery rate are expected to drive the penicillin G acylase market in the next few years. E. coli is a well-studied and well-characterized bacterium that is easy to manipulate genetically, which makes it an ideal organism for genetic engineering to optimize the production of PGA. It can be engineered to express high levels of PGA and to secrete the enzyme into the culture medium, which simplifies downstream processing.
E. coli is a low-cost organism that can be grown in large-scale fermentations using inexpensive carbon and nitrogen sources. This makes production of PGA from E. coli a cost-effective process that can be scaled up to meet the demands of the pharmaceutical industry. It is a non-pathogenic bacterium that is considered safe for use in the production of pharmaceuticals. Usage of E. coli as a source of PGA has been approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA).
Based on application, the production of semisynthetic penicillin segment accounted for leading market share in 2022. Production of semisynthetic penicillin is one of the most important applications of penicillin G acylases. This is ascribed to high demand for antibiotics in the healthcare sector and several advantages of semisynthetic penicillin over other types of antibiotics.
Semisynthetic penicillin is produced by modifying the structure of natural penicillin using penicillin G acylases. The modification process can produce penicillin, which is more effective against certain types of bacteria, has a longer half-life in the body, or is less susceptible to resistance than natural penicillin. This makes semisynthetic penicillin a highly valuable tool in the fight against infectious diseases, which continue to be a major public health challenge worldwide.
Demand for penicillin G acylases is high in the healthcare sector, as these are an important tool in the production of several types of antibiotics, including semi-synthetic penicillin. As the global population continues to grow and age, demand for antibiotics is expected to increase, which is likely to offer lucrative business opportunities to market players.
Based on end-user, the pharmaceutical companies segment led the global penicillin G acylase market in 2022. Penicillin G acylase is an enzyme used in the production of semisynthetic antibiotics, including ampicillin and amoxicillin. These antibiotics are widely used in the treatment of various bacterial infections, making them a vital component of the healthcare industry.
Pharmaceutical companies have significant resources and expertise in the development and production of drugs and pharmaceuticals. These have the necessary infrastructure, equipment, and technical know-how to develop and produce penicillin G acylase on a large scale, ensuring a reliable supply of the enzyme. These companies also have established distribution networks and sales channels that enable them to reach a broad customer base, including hospitals, clinics, and other healthcare facilities.
Pharmaceutical companies invest significantly in research & development to create new and innovative drugs and therapies. R&D often involves usage of penicillin G acylase in the production of new antibiotics, which further strengthens their position in the market.
North America accounted for significant global penicillin G acylase market share in 2022. Rise in prevalence of infectious diseases, such as tuberculosis, malaria, and respiratory infections is driving the market in the region. These conditions often require antibiotics for the treatment, which contributes to the rise in demand for PGA during the forecast period.
The market in Europe is driven by high demand for PGA among leading pharmaceutical companies and rise in adoption of semisynthetic penicillin and cephalosporin. For instance, pharmaceutical companies in Europe such as Merck KGaA and Biosynth are the key players in the market. These are major providers of PGA to academic and research institutes, CMO, etc. for manufacturing of semisynthetic antibiotics.
Increase in labor, energy, and raw material costs has resulted in shift of bulk manufacturing to the East, with China, South Korea, and India becoming major production hubs. Hence, the market in Asia Pacific is projected to witness rapid growth during the forecast period.
The market in Latin America is growing at a sluggish pace. However, the market is expected to experience moderate growth due to increase in usage of PGA in the production of semisynthetic antibiotics and rise in prevalence of infectious diseases.
The global penicillin G acylase market is fragmented, with the presence of large number of players. Key players operating in the market are Merck KGaA, Fermenta Biotech Ltd., Biosynth, Amicogen, Creative Enzymes, Crawford Wisdom International, and MuseChem Chemicals. These players engage in merger & acquisition, strategic collaborations, and new product launches to expand presence and gain market share.
The market report profiles the top players based on various factors including a company overview, financial summary, strategies, product portfolio, segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2022 |
US$ 672.5 Mn |
|
Forecast Value in 2031 |
More than US$ 1.1 Bn |
|
CAGR - 2022–2031 |
5.6% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Mn/Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
The global industry was valued at US$ 672.5 Mn in 2022.
It is projected to reach more than US$ 1.1 Bn by 2031.
The CAGR is anticipated to be 5.6% from 2023 to 2031.
The E. coli held more than 80.0% share in 2022.
North America is expected to account for largest share from 2023 to 2031.
Merck KGaA, Fermenta Biotech Ltd., Biosynth, Amicogen, Creative Enzymes, Crawford Wisdom International, and MuseChem Chemicals.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Penicillin G Acylase Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Penicillin G Acylase Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Penicillin G Acylase Preform and Immobilize form: An Overview
5.2. Regulatory Scenario by Region/globally
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Penicillin G Acylase Market Analysis and Forecast, By Source
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Source, 2017–2031
6.3.1. E. coli
6.3.2. Bacillus Megaterium
6.3.3. Others
6.4. Market Attractiveness Analysis, By Source
7. Global Penicillin G Acylase Market Analysis and Forecast, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Production of Semisynthetic Penicillin
7.3.2. Production of Semisynthetic Cephalosporin
7.3.3. Others
7.4. Market Attractiveness Analysis, By Application
8. Global Penicillin G Acylase Market Analysis and Forecast, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Pharmaceutical Companies
8.3.2. Academic & Research Institutes
8.3.3. Others
8.4. Market Attractiveness Analysis, By End-user
9. Global Penicillin G Acylase Market Analysis and Forecast, By Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, By Region
10. North America Penicillin G Acylase Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Source, 2017–2031
10.2.1. E. coli
10.2.2. Bacillus Megaterium
10.2.3. Others
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Production of Semisynthetic Penicillin
10.3.2. Production of Semisynthetic Cephalosporin
10.3.3. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Pharmaceutical Companies
10.4.2. Academic & Research Institutes
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Source
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Penicillin G Acylase Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Source, 2017–2031
11.2.1. E. coli
11.2.2. Bacillus Megaterium
11.2.3. Others
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Production of Semisynthetic Penicillin
11.3.2. Production of Semisynthetic Cephalosporin
11.3.3. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Pharmaceutical Companies
11.4.2. Academic & Research Institutes
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Source
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Penicillin G Acylase Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Source, 2017–2031
12.2.1. E. coli
12.2.2. Bacillus Megaterium
12.2.3. Others
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Production of Semisynthetic Penicillin
12.3.2. Production of Semisynthetic Cephalosporin
12.3.3. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Pharmaceutical Companies
12.4.2. Academic & Research Institutes
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Source
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Penicillin G Acylase Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Source, 2017–2031
13.2.1. E. coli
13.2.2. Bacillus Megaterium
13.2.3. Others
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Production of Semisynthetic Penicillin
13.3.2. Production of Semisynthetic Cephalosporin
13.3.3. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Pharmaceutical Companies
13.4.2. Academic & Research Institutes
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Source
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Penicillin G Acylase Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Source, 2017–2031
14.2.1. E. coli
14.2.2. Bacillus Megaterium
14.2.3. Others
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Production of Semisynthetic Penicillin
14.3.2. Production of Semisynthetic Cephalosporin
14.3.3. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Pharmaceutical Companies
14.4.2. Academic & Research Institutes
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & South Africa
14.6. Market Attractiveness Analysis
14.6.1. By Source
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. Merck KGaA (Sigma Aldrich)
15.2.1.1. Company Overview
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Business Strategies
15.2.1.5. Recent Developments
15.2.2. Fermenta Biotech Ltd.
15.2.2.1. Company Overview
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Business Strategies
15.2.2.5. Recent Developments
15.2.3. Biosynth
15.2.3.1. Company Overview
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Business Strategies
15.2.3.5. Recent Developments
15.2.4. Amicogen
15.2.4.1. Company Overview
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Business Strategies
15.2.4.5. Recent Developments
15.2.5. Creative Enzymes
15.2.5.1. Company Overview
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Business Strategies
15.2.5.5. Recent Developments
15.2.6. Crawford Wisdom International
15.2.6.1. Company Overview
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Business Strategies
15.2.6.5. Recent Developments
15.2.7. MuseChem Chemicals
15.2.7.1. Company Overview
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Business Strategies
15.2.7.5. Recent Developments
List of Tables
Table 01: Global Penicillin G Acylases Market Value (US$ Mn) Forecast, by Source, 2017‒2031
Table 02: Global Penicillin G Acylases Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Penicillin G Acylases Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Penicillin G Acylases Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Penicillin G Acylase Market Value (US$ Mn) Forecast, by Source, 2017‒2031
Table 06: North America Penicillin G Acylase Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 07: North America Penicillin G Acylase Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 08: North America Penicillin G Acylase Market Value (US$ Mn) Forecast, by Country, 2017‒2031
Table 09: Europe Penicillin G Acylase Market Value (US$ Mn) Forecast, by Source, 2017‒2031
Table 10: Europe Penicillin G Acylase Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 11: Europe Penicillin G Acylase Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Europe Penicillin G Acylase Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017‒2031
Table 13: Asia Pacific Penicillin G Acylase Market Value (US$ Mn) Forecast, by Source, 2017‒2031
Table 14: Asia Pacific Penicillin G Acylase Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 15: Asia Pacific Penicillin G Acylase Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 16: Asia Pacific Penicillin G Acylase Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031
Table 17: Latin America Penicillin G Acylase Market Value (US$ Mn) Forecast, by Source, 2017‒2031
Table 18: Latin America Penicillin G Acylase Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 19: Latin America Penicillin G Acylase Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 20: Latin America Penicillin G Acylase Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031
Table 21: Middle East & Africa Penicillin G Acylase Market Value (US$ Mn) Forecast, by Source, 2017‒2031
Table 22: Middle East & Africa Penicillin G Acylase Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 23: Middle East & Africa Penicillin G Acylase Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 24: Middle East & Africa Penicillin G Acylase Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031
List of Figures
Figure 01: Global Penicillin G Acylases Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Penicillin G Acylases Market Value Share, by Source, 2022
Figure 03: Global Penicillin G Acylases Market Value Share, by Application, 2022
Figure 04: Global Penicillin G Acylases Market Value Share, by End-user, 2022
Figure 05: Global Penicillin G Acylases Market Value Share Analysis, by Source, 2022 and 2031
Figure 06: Global Penicillin G Acylases Market Attractiveness Analysis, by Source, 2023–2031
Figure 07: Global Penicillin G Acylases Market Value (US$ Mn), by E. coli, 2017‒2031
Figure 08: Global Penicillin G Acylases Market Value (US$ Mn), by Bacillus Megaterium, 2017‒2031
Figure 09: Global Penicillin G Acylases Market Value (US$ Mn), by Others, 2017‒2031
Figure 10: Global Penicillin G Acylases Market Value Share Analysis, by Application, 2022 and 2031
Figure 11: Global Penicillin G Acylases Market Attractiveness Analysis, by Application, 2022–2031
Figure 12: Global Penicillin G Acylases Market Revenue (US$ Mn), by Production of Semisynthetic Penicillin, 2017–2031
Figure 13: Global Penicillin G Acylases Market Revenue (US$ Mn), by Production of Semisynthetic Cephalosporin, 2017–2031
Figure 14: Global Penicillin G Acylases Market Revenue (US$ Mn), by Others, 2017–2031
Figure 15: Global Penicillin G Acylases Market Value Share Analysis, by End-user, 2022 and 2031
Figure 16: Global Penicillin G Acylases Market Attractiveness Analysis, by End-user, 2023–2031
Figure 17: Global Penicillin G Acylases Market Revenue (US$ Mn), by Pharmaceutical Companies, 2017–2031
Figure 18: Global Penicillin G Acylases Market Revenue (US$ Mn), by Academic & Research Institutes, 2017–2031
Figure 19: Global Penicillin G Acylases Market Revenue (US$ Mn), by Others, 2017–2031
Figure 20: Global Penicillin G Acylases Market Value Share Analysis, by Region, 2022 and 2031
Figure 21: Global Penicillin G Acylases Market Attractiveness Analysis, by Region, 2023–2031
Figure 22: North America Penicillin G Acylase Market Value (US$ Mn) Forecast, 2017–2031
Figure 23: North America Penicillin G Acylase Market Value Share Analysis, by Source, 2022 and 2031
Figure 24: North America Penicillin G Acylase Market Attractiveness Analysis, by Source, 2023–2031
Figure 25: North America Penicillin G Acylase Market Value Share Analysis, by Application, 2022 and 2031
Figure 26: North America Penicillin G Acylase Market Attractiveness Analysis, by Application, 2023–2031
Figure 27: North America Penicillin G Acylase Market Value Share Analysis, by End-user, 2022 and 2031
Figure 28: North America Penicillin G Acylase Market Attractiveness Analysis, by End-user, 2023–2031
Figure 29: North America Penicillin G Acylase Market Value Share Analysis, by Country, 2022 and 2031
Figure 30: North America Penicillin G Acylase Market Attractiveness Analysis, by Country, 2023–2031
Figure 31: Europe Penicillin G Acylase Market Value (US$ Mn) Forecast, 2017–2031
Figure 32: Europe Penicillin G Acylase Market Value Share Analysis, by Source, 2022 and 2031
Figure 33: Europe Penicillin G Acylase Market Attractiveness Analysis, by Source, 2023–2031
Figure 34: Europe Penicillin G Acylase Market Value Share Analysis, by Application, 2022 and 2031
Figure 35: Europe Penicillin G Acylase Market Attractiveness Analysis, by Application, 2023–2031
Figure 36: Europe Penicillin G Acylase Market Value Share Analysis, by End-user, 2022 and 2031
Figure 37: Europe Penicillin G Acylase Market Attractiveness Analysis, by End-user, 2023–2031
Figure 38: Europe Penicillin G Acylase Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Europe Penicillin G Acylase Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 40: Asia Pacific Penicillin G Acylase Market Value (US$ Mn) Forecast, 2017–2031
Figure 41: Asia Pacific Penicillin G Acylase Market Value Share Analysis, by Source, 2022 and 2031
Figure 42: Asia Pacific Penicillin G Acylase Market Attractiveness Analysis, by Source, 2023–2031
Figure 43: Asia Pacific Penicillin G Acylase Market Value Share Analysis, by Application, 2022 and 2031
Figure 44: Asia Pacific Penicillin G Acylase Market Attractiveness Analysis, by Application, 2023–2031
Figure 45: Asia Pacific Penicillin G Acylase Market Value Share Analysis, by End-user, 2022 and 2031
Figure 46: Asia Pacific Penicillin G Acylase Market Attractiveness Analysis, by End-user, 2023–2031
Figure 47: Asia Pacific Penicillin G Acylase Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Asia Pacific Penicillin G Acylase Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 49: Latin America Penicillin G Acylase Market Value (US$ Mn) Forecast, 2017–2031
Figure 50: Latin America Penicillin G Acylase Market Value Share Analysis, by Source, 2022 and 2031
Figure 51: Latin America Penicillin G Acylase Market Attractiveness Analysis, by Source, 2023–2031
Figure 52: Latin America Penicillin G Acylase Market Value Share Analysis, by Application, 2022 and 2031
Figure 53: Latin America Penicillin G Acylase Market Attractiveness Analysis, by Application, 2023–2031
Figure 54: Latin America Penicillin G Acylase Market Value Share Analysis, by End-user, 2022 and 2031
Figure 55: Latin America Penicillin G Acylase Market Attractiveness Analysis, by End-user, 2023–2031
Figure 56: Latin America Penicillin G Acylase Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Latin America Penicillin G Acylase Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 58: Middle East & Africa Penicillin G Acylase Market Value (US$ Mn) Forecast, 2017–2031
Figure 59: Middle East & Africa Penicillin G Acylase Market Value Share Analysis, by Source, 2022 and 2031
Figure 60: Middle East & Africa Penicillin G Acylase Market Attractiveness Analysis, by Source, 2023–2031
Figure 61: Middle East & Africa Penicillin G Acylase Market Value Share Analysis, by Application, 2022 and 2031
Figure 62: Middle East & Africa Penicillin G Acylase Market Attractiveness Analysis, by Application, 2023–2031
Figure 63: Middle East & Africa Penicillin G Acylase Market Value Share Analysis, by End-user, 2022 and 2031
Figure 64: Middle East & Africa Penicillin G Acylase Market Attractiveness Analysis, by End-user, 2023–2031
Figure 65: Middle East & Africa Penicillin G Acylase Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 66: Middle East & Africa Penicillin G Acylase Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Penicillin G Acylase Market
*86 figures and 60 tables includes